Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREOPANC-5 for resectable or borderline resectable pancreatic cancer
NL-OMON60816Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and mFOLFIRINOX in pancreatic cancer (PC), sponsored by Amsterdam University Medical Center. Primary endpoint: Progression-free survival. Started Sep 2024; status: recruiting.
02
Drugs
pembrolizumabmFOLFIRINOX
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON60816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60816.